ArticleTranslational oncology2021
Evaluation of therapeutic efficacy of
Article in Translational oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Attenuated Toxicity and Antitoxic Mechanism via Sodium Iodide Symporter Inhibition-Based Tumor-Selective Delivery in Astatine-211 Radioimmunotherapy.Molecular pharmaceutics · 2026Article
- A Scoping Review of the Challenges and Future Perspectives in the Use of Alpha-Emitters for Metastatic Ovarian Cancer.Molecules (Basel, Switzerland) · 2026Article
- Astatine-211-Towards In Vivo Stable Astatine-211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications.Medicinal research reviews · 2026Review
- Review
- Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Enhanced activity localization and microscale dosimetry in alpha-emitter radiopharmaceutical therapy using integrated autoradiography and histological imaging.Scientific reports · 2025Article
- Astatine-211 and actinium-225: two promising nuclides in targeted alpha therapy.Acta biochimica et biophysica Sinica · 2024Review
- Behaviour, use and safety aspects of astatine-211 solvated in chloroform after dry distillation recovery.Scientific reports · 2024Article
- A Novel Method for Real-Time Quantification of Radioligand Binding to Living Tumor CellsCancer biotherapy & radiopharmaceuticals · 2024Article
- Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer.Theranostics · 2024Review
- Astatine-211 based radionuclide therapy: Current clinical trial landscape.Frontiers in medicine · 2022Review
- Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".Pharmaceutics · 2021Review
- Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer.Nuclear medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAntibodies labeled with alpha-emitter astatine-211 have previously shown effective in intraperitoneal (i.p.) treatments of ovarian cancer. In the present work we explore the use of investigational farletuzumab, aimed at the folate receptor alpha. The aim was to evaluate the biodistribution and therapeutic effect of
methodsFor biodistribution, using intravenous injections and mice carrying subcutaneous (s.c.) tumors, the animals were administered either
resultsThe biodistribution of
conclusionThe current investigation of intraperitoneal therapy with
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.